Clal Insurance’s Novo Nordisk NVO Stock Holding History

Clal Insurance’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,000	Closed	-$721K	–	226
2025 Q3	$721K	Hold	13,000	–	–	0.01%	109
2025 Q2	$897K	Hold	13,000	–	–	0.01%	100
2025 Q1	$918K	Buy	13,000 +3,000	+30%	+$248K	0.01%	97
2024 Q4	$860K	Buy	10,000 +4,000	+67%	+$433K	0.01%	91
2024 Q3	$714K	Buy	+6,000	New	+$800K	0.01%	102
2023 Q1	–	Sell	-14,000	Closed	-$947K	–	155
2022 Q4	$947K	Buy	14,000 +2,000	+17%	+$117K	0.01%	126
2022 Q3	$598K	Hold	12,000	–	–	0.01%	133
2022 Q2	$669K	Sell	12,000 -12,000	-50%	-$666K	0.01%	138
2022 Q1	$1.33M	Buy	+24,000	New	+$1.23M	0.01%	132
2021 Q3	–	Sell	-15,000	Closed	-$628K	–	234
2021 Q2	$628K	Sell	15,000 -7,000	-32%	-$271K	0.01%	166
2021 Q1	$752K	Hold	22,000	–	–	0.01%	153
2020 Q4	$718K	Buy	22,000 +6,000	+38%	+$207K	0.01%	114
2020 Q3	$555K	Hold	16,000	–	–	0.01%	113
2020 Q2	$524K	Sell	16,000 -4,000	-20%	-$128K	0.01%	114
2020 Q1	$610K	Buy	+20,000	New	+$596K	0.02%	99

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Clal Insurance's NVO Position: Q4 2025 in Review

Clal Insurance sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 13,000 shares — an estimated $721K sold.

Clal Insurance first reported a position in NVO in Q1 2020 and held it in 15 quarters. The position peaked at $1.33M in Q1 2022. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Clal Insurance reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
Clal Insurance sold 13,000 Novo Nordisk shares in Q4 2025, an estimated $721K.
Clal Insurance first reported a position in Novo Nordisk in Q1 2020 and held it in 15 quarters.
Clal Insurance's Novo Nordisk position peaked at $1.33M in Q1 2022.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Clal Insurance's 13F filing for Q4 2025, filed 13 Feb 2026.